Patricia S. Andrews net worth and biography

Patricia Andrews Biography and Net Worth

Director of Oncolytics Biotech

Ms. Andrews has been a member of the Oncolytics board since January 2024. Ms. Andrews was the CEO of Sumitomo Pharma Oncology, Inc., a clinical-stage research and development biopharmaceutical company, and Global Head of Oncology and an Executive Officer for Sumitomo Pharma Co., Ltd. from 2017 to 2023. Prior to joining this organization in 2013, she was Executive Vice President and Chief Commercial Officer at Incyte for four years, where she established the commercial organization and launched its first-in-class, first-in-disease oncology product Jakafi®. She was also responsible for business development and completed multiple significant product licensing deals for Incyte. Ms. Andrews held increasing leadership positions at Pfizer from 1991-2008, with her final role being Vice President and General Manager of the U.S. Oncology Business Unit. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University. Ms. Andrews also serves on the board of GlycoMimetics.

What is Patricia S. Andrews' net worth?: The estimated net worth of Patricia S. Andrews is at least $65.49 thousand as of February 12th, 2026. Ms. Andrews owns 78,128 shares of Oncolytics Biotech stock worth more than $65,487 as of September 1st. This net worth estimate does not reflect any other investments that Ms. Andrews may own. Learn More about Patricia S. Andrews' net worth.
How do I contact Patricia S. Andrews?: The corporate mailing address for Ms. Andrews and other Oncolytics Biotech executives is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. Oncolytics Biotech can also be reached via phone at (403) 670-7377 and via email at [email protected]. Learn More on Patricia S. Andrews' contact information.
Has Patricia S. Andrews been buying or selling shares of Oncolytics Biotech?: Patricia S. Andrews has not been actively trading shares of Oncolytics Biotech over the course of the past ninety days. Most recently, on Thursday, February 12th, Patricia S. Andrews bought 35,400 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of $0.86 per share, with a total value of $30,444.00. Following the completion of the transaction, the director now directly owns 78,128 shares of the company's stock, valued at $67,190.08. Learn More on Patricia S. Andrews' trading history.
Who are Oncolytics Biotech's active insiders?: Oncolytics Biotech's insider roster includes Patricia Andrews (Director), Andrew Aromando (Chief Business Officer), Deborah Brown (Director), Allison Hagerman (Chief Technology Officer), Jared Kelly (Chief Executive Officer & Director), Kirk Look (CFO), James Parsons (Director), and Bernd Seizinger (Director). Learn More on Oncolytics Biotech's active insiders.
Are insiders buying or selling shares of Oncolytics Biotech?: During the last year, Oncolytics Biotech insiders bought shares 14 times. They purchased a total of 404,282 shares worth more than $363,231.56. The most recent insider tranaction occured on March, 12th when CEO Jared Kelly bought 5,050 shares worth more than $4,848.00. Insiders at Oncolytics Biotech own 0.1% of the company. Learn More about insider trades at Oncolytics Biotech.
Information on this page was last updated on 3/12/2026.

Patricia S. Andrews Insider Trading History at Oncolytics Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/12/2026	Buy	35,400	$0.86	$30,444.00	78,128

Patricia S. Andrews Buying and Selling Activity at Oncolytics Biotech

Oncolytics Biotech Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: $0.84

$0.83

$0.87

50 Day Range

MA: $0.85

$0.75

$0.96

2 Week Range

Now: $0.84

$0.73

$1.51

Volume

428,783 shs

Average Volume

644,143 shs

Market Capitalization

$106.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13